Danaher (DHR) Scheduled to Post Quarterly Earnings on Tuesday

Danaher (NYSE:DHRGet Free Report) is set to announce its earnings results before the market opens on Tuesday, April 23rd. Analysts expect the company to announce earnings of $1.74 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The firm had revenue of $6.41 billion for the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter last year, the company earned $2.87 earnings per share. The business’s revenue for the quarter was down 10.2% compared to the same quarter last year. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Danaher Stock Performance

NYSE:DHR opened at $235.51 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher has a 12-month low of $182.09 and a 12-month high of $259.00. The stock has a 50-day moving average price of $248.94 and a 200 day moving average price of $230.15. The stock has a market capitalization of $174.41 billion, a P/E ratio of 36.86, a P/E/G ratio of 3.59 and a beta of 0.83.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.46%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is currently 16.90%.

Insider Activity at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Walter G. Lohr sold 3,289 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the transaction, the director now owns 14,129 shares in the company, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,957 shares of company stock worth $8,265,802. Company insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Institutional investors have recently modified their holdings of the company. Moneta Group Investment Advisors LLC increased its position in Danaher by 96,490.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock worth $6,180,839,000 after buying an additional 23,262,904 shares in the last quarter. Norges Bank bought a new stake in shares of Danaher in the 4th quarter valued at approximately $2,057,164,000. Legal & General Group Plc increased its position in Danaher by 24.8% in the fourth quarter. Legal & General Group Plc now owns 5,854,168 shares of the conglomerate’s stock worth $1,354,305,000 after buying an additional 1,163,251 shares during the period. CI Private Wealth LLC acquired a new stake in Danaher in the fourth quarter worth $181,103,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Danaher by 84.7% during the first quarter. Renaissance Technologies LLC now owns 818,436 shares of the conglomerate’s stock valued at $240,072,000 after purchasing an additional 375,400 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DHR. Raymond James raised their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their target price for the company from $250.00 to $280.00 in a research report on Wednesday. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Barclays lifted their price target on Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, April 10th. Finally, Royal Bank of Canada lifted their price target on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $268.27.

Get Our Latest Research Report on Danaher

About Danaher

(Get Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Earnings History for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.